Abstract
Intraductal papillary mucinous neoplasms (IPMN) of the pancreas are premalignant mucin-producing epithelial tumors that arise from the pancreatic ductal system. These cystic tumors represent 15–30% of cystic lesions of the pancreas [Basturk et al. in Am J Surg Pathol 39(12):1730–1741, 1; Ferrone et al. in Arch Surg (Chicago, Ill: 1960) 144(5):448–454, 2, Kosmahl et al. in Virchows Arch Int J Pathol 445(2):168–178, 3; Spinelli et al. in Ann Surg. 239(5):651–657, 4]. It is believed that IPMN can progress from low-grade dysplasia to high-grade dysplasia to invasive cancer, and this pathway of progression accounts for 20–30% of pancreatic cancer [Adsay et al. in Am J Surg Pathol 28(7):839–848, 5; Tanaka et al. in J Gastroenterol 40(7):669–675, 6; Wu et al. in Sci Transl Med 3(92):92ra66, 7]. Furthermore, it is also widely believed that IPMN represent a field defect of the pancreas in which the entire ductal system is at risk of developing invasive carcinoma, not only in the area of radiographically detectable IPMN, and thus the remaining gland should undergo surveillance after partial pancreatectomy [Salvia et al. in Ann Surg 239(5):678–685, 8; Izawa et al. in Cancer 92(7):1807–1817, 9; Yamaguchi and Tanaka in Jpn J Clin Oncol 41(7):836–840, 10]. Increasingly, surgeons are faced with the dilemma between recommending highly complex resections—that have significant morbidity and mortality—in patients who may have low-risk IPMN (low-grade dysplasia), or alternatively, recommending observation for those who could possibly be harboring a radiographically occult malignancy. Given the complexity of the management decisions for patients with IPMN, the purpose of this paper is to review the current literature and to provide a summary of how accurate we are currently with the identification of high-grade dysplasia or progression to carcinoma in patients who present with IPMN.
Similar content being viewed by others
References
Basturk O, Hong SM, Wood LD et al (2015) A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39(12):1730–1741
Ferrone CR, Correa-Gallego C, Warshaw AL et al (2009) Current trends in pancreatic cystic neoplasms. Arch Surg (Chicago, Ill: 1960) 144(5):448–454
Kosmahl M, Pauser U, Peters K et al (2004) Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal. Virchows Arch Int J Pathol 445(2):168–178
Spinelli KS, Fromwiller TE, Daniel RA et al (2004) Cystic pancreatic neoplasms: observe or operate. Ann Surg. 239(5):651–657 (discussion 657–659)
Adsay NV, Merati K, Basturk O et al (2004) Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol 28(7):839–848
Tanaka M, Kobayashi K, Mizumoto K, Yamaguchi K (2005) Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol 40(7):669–675
Wu J, Matthaei H, Maitra A et al (2011) Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3(92):92ra66
Salvia R, Fernandez-del Castillo C, Bassi C et al (2004) Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 239(5):678–685 (discussion 685–677)
Izawa T, Obara T, Tanno S, Mizukami Y, Yanagawa N, Kohgo Y (2001) Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas. Cancer 92(7):1807–1817
Yamaguchi K, Tanaka M (2011) EBM-based clinical guidelines for pancreatic cancer 2009 from the Japan Pancreas Society: a synopsis. Jpn J Clin Oncol 41(7):836–840
Wu J, Jiao Y, Dal Molin M et al (2011) Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 108(52):21188–21193
de Jong K, Nio CY, Mearadji B et al (2012) Disappointing interobserver agreement among radiologists for a classifying diagnosis of pancreatic cysts using magnetic resonance imaging. Pancreas 41(2):278–282
Laffan TA, Horton KM, Klein AP et al (2008) Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 191(3):802–807
Gorin AD, Sackier JM (1997) Incidental detection of cystic neoplasms of the pancreas. Md Med J (Baltimore, Md: 1985) 46(2):79–82
Fernandez-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL (2003) Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg (Chicago, Ill: 1960) 138(4):427–434 (discussion 433–424)
Lee JH, Lee KT, Park J et al (2010) Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms. World J Gastroenterol 16(42):5353–5358
Gaujoux S, Brennan MF, Gonen M et al (2011) Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. J Am Coll Surg 212(4):590–600 (discussion 600–593)
Valsangkar NP, Morales-Oyarvide V, Thayer SP et al (2012) 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery 152(3 Suppl 1):S4–12
Tanaka M, Fernandez-del Castillo C, Adsay V et al (2012) International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12(3):183–197
Del Chiaro M, Verbeke C, Salvia R et al (2013) European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis 45(9):703–711
European Study Group on Cystic Tumours of the P (2018) European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67(5):789–804
Vege SS, Ziring B, Jain R, Moayyedi P (2015) American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 148(4):819–822 (quize 812–813)
Nakamura M, Miyasaka Y, Sadakari Y, Date K, Ohtsuka T (2017) Comparison of guidelines for intraductal papillary mucinous neoplasm: what is the next step beyond the current guidelines? Ann Gastroenterol Surg 1(2):90–98
Lekkerkerker SJ, Besselink MG, Busch OR et al (2017) Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcome. Gastrointest Endosc 85(5):1025–1031
Tanaka M, Fernandez-Del Castillo C, Kamisawa T et al (2017) Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17(5):738–753
Shimizu Y, Yamaue H, Maguchi H et al (2015) Validation of a nomogram for predicting the probability of carcinoma in patients with intraductal papillary mucinous neoplasm in 180 pancreatic resection patients at 3 high-volume centers. Pancreas 44(3):459–464
Jang JY, Park T, Lee S et al (2017) Proposed nomogram predicting the individual risk of malignancy in the patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 266(6):1062–1068
Attiyeh MA, Fernandez-Del Castillo C, Al Efishat M et al (2018) Development and validation of a multi-institutional preoperative nomogram for predicting grade of dysplasia in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: a report from the pancreatic surgery consortium. Ann Surg 267(1):157–163
Correa-Gallego C, Do R, Lafemina J et al (2013) Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram. Ann Surg Oncol 20(13):4348–4355
Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL (2006) Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24(18):2897–2902
Sandblom G, Granroth S, Rasmussen IC (2008) TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci 113(1):57–64
Sultana A, Jackson R, Tim G et al (2015) What is the best way to identify malignant transformation within pancreatic IPMN: a systematic review and meta-analyses. Clin Transl Gastroenterol 6:e130
Megibow AJ, Baker ME, Morgan DE et al (2017) Management of incidental pancreatic cysts: a white paper of the ACR incidental findings committee. J Am Coll Radiol JACR 14(7):911–923
Sahani DV, Kambadakone A, Macari M, Takahashi N, Chari S, Fernandez-del Castillo C (2013) Diagnosis and management of cystic pancreatic lesions. AJR Am J Roentgenol 200(2):343–354
Visser BC, Yeh BM, Qayyum A, Way LW, McCulloch CE, Coakley FV (2007) Characterization of cystic pancreatic masses: relative accuracy of CT and MRI. AJR Am J Roentgenol 189(3):648–656
Chaudhari VV, Raman SS, Vuong NL et al (2008) Pancreatic cystic lesions: discrimination accuracy based on clinical data and high-resolution computed tomographic features. J Comput Assist Tomogr 32(5):757–763
Nougaret S, Reinhold C, Chong J et al (2014) Incidental pancreatic cysts: natural history and diagnostic accuracy of a limited serial pancreatic cyst MRI protocol. Eur Radiol 24(5):1020–1029
Chen FM, Ni JM, Zhang ZY, Zhang L, Li B, Jiang CJ (2016) Presurgical evaluation of pancreatic cancer: a comprehensive imaging comparison of CT versus MRI. AJR Am J Roentgenol 206(3):526–535
Hwang DW, Jang JY, Lim CS et al (2011) Determination of malignant and invasive predictors in branch duct type intraductal papillary mucinous neoplasms of the pancreas: a suggested scoring formula. J Korean Med Sci 26(6):740–746
Sainani NI, Saokar A, Deshpande V, Fernandez-del Castillo C, Hahn P, Sahani DV (2009) Comparative performance of MDCT and MRI with MR cholangiopancreatography in characterizing small pancreatic cysts. AJR Am J Roentgenol 193(3):722–731
Kang KM, Lee JM, Shin CI et al (2013) Added value of diffusion-weighted imaging to MR cholangiopancreatography with unenhanced mr imaging for predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm of the pancreas. J Magn Reson Imaging JMRI. 38(3):555–563
Kim JH, Eun HW, Park HJ, Hong SS, Kim YJ (2012) Diagnostic performance of MRI and EUS in the differentiation of benign from malignant pancreatic cyst and cyst communication with the main duct. Eur J Radiol 81(11):2927–2935
Macari M, Finn ME, Bennett GL et al (2009) Differentiating pancreatic cystic neoplasms from pancreatic pseudocysts at MR imaging: value of perceived internal debris. Radiology 251(1):77–84
Pozzi-Mucelli RM, Rinta-Kiikka I, Wunsche K et al (2017) Pancreatic MRI for the surveillance of cystic neoplasms: comparison of a short with a comprehensive imaging protocol. Eur Radiol 27(1):41–50
Choi SY, Kim JH, Yu MH, Eun HW, Lee HK, Han JK (2017) Diagnostic performance and imaging features for predicting the malignant potential of intraductal papillary mucinous neoplasm of the pancreas: a comparison of EUS, contrast-enhanced CT and MRI. Abdom Radiol (N Y) 42(5):1449–1458
Ridtitid W, DeWitt JM, Schmidt CM et al (2016) Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes. Gastrointest Endosc 84(3):436–445
Ahmad NA, Kochman ML, Lewis JD, Ginsberg GG (2001) Can EUS alone differentiate between malignant and benign cystic lesions of the pancreas? Am J Gastroenterol 96(12):3295–3300
Emaminejad N, Qian W, Guan Y et al (2016) Fusion of quantitative image and genomic biomarkers to improve prognosis assessment of early stage lung cancer patients. IEEE Trans Biomed Eng 63(5):1034–1043
Lloyd MC, Allam-Nandyala P, Purohit CN, Burke N, Coppola D, Bui MM (2010) Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: how reliable is it? J Pathol Inform 1:29
Cameron A, Khalvati F, Haider MA, Wong A (2016) MAPS: a quantitative radiomics approach for prostate cancer detection. IEEE Trans Biomed Eng 63(6):1145–1156
Chakraborty J, Midya A, Gazit L et al (2018) CT radiomics to predict high-risk intraductal papillary mucinous neoplasms of the pancreas. Med Phys 45(11):5019–5029
Permuth JB, Choi J, Balarunathan Y et al (2016) Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget 7(52):85785–85797
Hanania AN, Bantis LE, Feng Z et al (2016) Quantitative imaging to evaluate malignant potential of IPMNs. Oncotarget 7(52):85776–85784
Attiyeh MA, Chakraborty J, Gazit L et al (2019) Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis. HPB 21(2):212–218
Furukawa T, Kloppel G, Volkan Adsay N et al (2005) Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Archi Int J Pathol 447(5):794–799
Furukawa T, Hatori T, Fujita I et al (2011) Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 60(4):509–516
Patra KC, Bardeesy N, Mizukami Y (2017) Diversity of precursor lesions for pancreatic cancer: the genetics and biology of intraductal papillary mucinous neoplasm. Clin Transl Gastroenterol 8(4):e86
Al-Refaie WB, Choi EA, Tseng JF et al (2006) Intraductal papillary mucinous neoplasms of the pancreas. Med Princ Pract Int J Kuwait Univ Health Sci Cent 15(4):245–252
Tan MC, Basturk O, Brannon AR et al (2015) GNAS and KRAS mutations define separate progression pathways in intraductal papillary mucinous neoplasm-associated carcinoma. J Am Coll Surg 220(5):845–854.e841
Yopp AC, Katabi N, Janakos M et al (2011) Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg 253(5):968–974
Winter JM, Jiang W, Basturk O et al (2016) Recurrence and survival after resection of small intraductal papillary mucinous neoplasm-associated carcinomas (≤ 20-mm invasive component): a multi-institutional analysis. Ann Surg 263(4):793–801
Basturk O, Tan M, Bhanot U et al (2016) The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol 29(9):1058–1069
Maker AV, Katabi N, Gonen M et al (2011) Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 18(1):199–206
Khalid A, Zahid M, Finkelstein SD et al (2009) Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 69(6):1095–1102
Singhi AD, Nikiforova MN, McGrath K (2017) DNA testing of pancreatic cyst fluid: is it ready for prime time? Lancet Gastroenterol Hepatol 2(1):63–72
Das KK, Xiao H, Geng X et al (2014) mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN). Gut 63(10):1626–1634
Maker AV, Hu V, Kadkol SS et al (2019) Cyst fluid biosignature to predict intraductal papillary mucinous neoplasms of the pancreas with high malignant potential. J Am Coll Surg 228(5):721–729
Al Efishat MA, Attiyeh MA, Eaton AA et al (2018) Multi-institutional validation study of pancreatic cyst fluid protein analysis for prediction of high-risk intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 268(2):340–347
Bournet B, Vignolle-Vidoni A, Grand D et al (2016) Endoscopic ultrasound-guided fine-needle aspiration plus KRAS and GNAS mutation in malignant intraductal papillary mucinous neoplasm of the pancreas. Endosc Int Open 4(12):E1228–e1235
Sausen M, Phallen J, Adleff V et al (2015) Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 6:7686
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
The research did not involve human participant or animals.
Informed consent
Not applicable for this type of study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lim, J., Allen, P.J. The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made?. Updates Surg 71, 209–216 (2019). https://doi.org/10.1007/s13304-019-00661-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13304-019-00661-0